Nicotinamide-d4
(Synonyms: 氘代烟酰胺,Niacinamide-d4; Nicotinic acid amide-d4) 目录号 : GC49270An internal standard for the quantification of nicotinamide
Cas No.:347841-88-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Nicotinamide-d4 is intended for use as an internal standard for the quantification of nicotinamide by GC- or LC-MS. Nicotinamide is an amide form of niacin, which is also known as vitamin B3, that can be biosynthesized in vivo or obtained through the diet.1 It is a precursor in the synthesis of the metabolic cofactor NAD+ and an inhibitor of sirtuin 1 (SIRT1; IC50 = <50 µM).2 Nicotinamide (10 µM) increases the activity of serine palmitoyltransferase (SPT) and the biosynthesis of ceramide, glucosylceramide, sphingomyelin, free fatty acids, and cholesterol in primary human keratinocytes.3 Nicotinamide (40 µM) induces apoptosis in SNU-398, SNU-739, and HepG2 hepatocellular carcinoma (HCC) cells, and it prevents the formation of neoplastic lesions in a diethylnitrosamine-induced mouse model of HCC.4 Unlike niacin, nicotinamide does not reduce plasma lipid levels or induce flushing.5,6,7
1.Li, F., Chong, Z.Z., and Maiese, K.Cell life versus cell longevity: The mysteries surrounding the NAD+ precursor nicotinamideCurr. Med. Chem.13(8)883-895(2006) 2.Bitterman, K.J., Anderson, R.M., Cohen, H.Y., et al.Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1J. Biol. Chem.277(47)45099-45107(2002) 3.Tanno, O., Ota, Y., Kitamura, N., et al.Nicotinamide increases biosynthesis of ceramides as well as other stratum corneum lipids to improve the epidermal permeability barrierBr. J. Dermatol.143(3)524-531(2000) 4.Park, S.Y., Lee, K.B., Lee, M.-J., et al.Nicotinamide inhibits the early stage of carcinogen-induced hepatocarcinogenesis in mice and suppresses human hepatocellular carcinoma cell growthJ. Cell. Physiol.227(3)899-908(2012) 5.Lukasova, M., Hanson, J., Tunaru, S., et al.Nicotinic acid (niacin): New lipid-independent mechanisms of action and therapeutic potentialsTrends Pharmacol. Sci.32(12)700-707(2011) 6.Bodor, E.T., and Offermanns, S.Nicotinic acid: An old drug with a promising futureBr. J. Pharmacol.153(Suppl 1)S68-S75(2008) 7.Haining, C.G.Effects of anti-rheumatic compounds and pyridine derivatives on the cutaneous response to thurfyl nicotinate in the guinea-pigBr. J. Pharmacol. Chemother.21(1)104-112(1963)
| Cas No. | 347841-88-7 | SDF | |
| 别名 | 氘代烟酰胺,Niacinamide-d4; Nicotinic acid amide-d4 | ||
| Canonical SMILES | NC(C1=C([2H])N=C([2H])C([2H])=C1[2H])=O | ||
| 分子式 | C6H2D4N2O | 分子量 | 126.2 |
| 溶解度 | DMF: 15 mg/ml,DMSO: 15 mg/ml,Ethanol: 2.5 mg/ml,PBS (pH 7.2): 10 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 7.9239 mL | 39.6197 mL | 79.2393 mL |
| 5 mM | 1.5848 mL | 7.9239 mL | 15.8479 mL |
| 10 mM | 0.7924 mL | 3.962 mL | 7.9239 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。